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macrophage responses to cytokine stimuli
but reduces their phagocytic activity
Sofia Pavlou, Jaime Lindsay, Rebecca Ingram, Heping Xu and Mei Chen*Abstract
Background: Macrophages are tissue resident immune cells important for host defence and homeostasis.
During diabetes, macrophages and other innate immune cells are known to have a pro-inflammatory
phenotype, which is believed to contribute to the pathogenesis of various diabetic complications. However,
diabetic patients are highly susceptible to bacterial infections, and often have impaired wound healing. The
molecular mechanism underlying the paradox of macrophage function in diabetes is not fully understood.
Recent evidence suggests that macrophage functions are governed by metabolic reprograming. Diabetes is a
disorder that affects glucose metabolism; dysregulated macrophage function in diabetes may be related to
alterations in their metabolic pathways. In this study, we seek to understand the effect of high glucose
exposure on macrophage phenotype and functions.
Results: Bone marrow cells were cultured in short or long term high glucose and normal glucose medium;
the number and phenotype of bone marrow derived macrophages were not affected by long-term high
glucose treatment. Short-term high glucose increased the expression of IL-1β. Long-term high glucose
increased the expression of IL-1β and TNFα but reduced the expression of IL-12p40 and nitric oxide
production in M1 macrophage. The treatment also increased Arg-1 and IL-10 expression in M2 macrophages.
Phagocytosis and bactericidal activity was reduced in long-term high glucose treated macrophages and
peritoneal macrophages from diabetic mice. Long-term high glucose treatment reduced macrophage
glycolytic capacity and glycolytic reserve without affecting mitochondrial ATP production and oxidative
respiration.
Conclusion: Long-term high glucose sensitizes macrophages to cytokine stimulation and reduces
phagocytosis and nitric oxide production, which may be related to impaired glycolytic capacity.
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Macrophages are tissue resident immune cells important
for host defence and homeostasis. During inflammation,
circulating monocytes are recruited and differentiated
into macrophages at the site of tissue damage and infec-
tion. The key functions of these macrophages are to
eliminate insults or pathogens and to promote tissue
repair. During diabetes, macrophages and other innate
immune cells are known to have a pro-inflammatory* Correspondence: m.chen@qub.ac.uk
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genesis of various diabetic complications, including dia-
betic nephropathy, atherosclerosis, and retinopathy [1].
Uncontrolled monocyte and neutrophil activation may
contribute to diabetes-mediated vascular damage through
abnormal leukocyte-endothelial interaction or leukostasis
[2, 3]. Inhibition of inflammation has been proposed as a
therapeutic approach for diabetic complications [4, 5].
However, diabetic patients are highly susceptible to bac-
terial infections, and often have impaired wound healing
[6]. It is believed that this is partially related to the re-
duced bactericidal function and wound healing capacity of
innate immune cells in diabetic patients. The molecularle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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tion in diabetes is not fully understood.
Recent evidence suggests that macrophage functions
are governed by metabolic reprograming [7]. Metabolic
pathways not only provide energy in the form of adeno-
sine triphosphate (ATP), but also regulate macrophage
functions [7]. For example, during acute inflammation,
the classically activated macrophages (M1) predomin-
ately utilize glycolysis, but not mitochondrial oxidative
phosphorylation, to support their inflammatory function
[8]. This metabolic pathway generates amino acids, ri-
bose and nicotinamide adenine dinucleotide phosphate
(NADPH) that are necessary for cytokine synthesis,
DNA replication and production of reactive oxygen spe-
cies (ROS) [7]. In addition, glycolytic enzymes and inter-
mediate products are actively involved in the regulation
of cytokine production. The pyruvate kinase M2 (PKM2)
has been shown to induce IL-1β expression through ac-
tivating hypoxia inducible factor 1, alpha subunit
(HIF1α) [8], whereas succinate enhances the stabilization
of HIF1α and supports IL-1β expression [9]. Since dia-
betes is a disorder that affects glucose metabolism, we
seek to understand whether dysregulated macrophage
function in diabetes is related to alterations in their
metabolic pathways.
In this study, we investigated the effect of high glucose
on bone marrow cell proliferation and differentiation
into macrophages. We further investigated the metabolic
pathways of macrophages generated under high glucose
and normal glucose conditions and how this is related to
their functions. We found that sustained high glucose
treatment impairs the glycolysis pathway in macro-
phages, which may be related to their reduced bacteri-
cidal activity and ROS production.
Results
The effect of long-term high glucose on bone marrow cell
proliferation and differentiation
In diabetes, myeloid progenitor cells are subjected to sus-
tained high glucose conditions. To investigate the impact
of the sustained hyperglycaemic environment on macro-
phage progenitors, we generated BMDMs under high glu-
cose DMEM (HighGlu) conditions. Flow cytometric
analysis showed that over 96% of cells were F4/80+
(Fig. 1a). The percentage and absolute number of F4/80+
macrophages were similar in BMDMs generated under
normal glucose DMEM ( NormGlu) and HighGlu condi-
tions (Fig. 1a). MTT assay further confirmed that the cell
numbers from different groups were also similar (Fig. 1b).
Ki67 is a nuclear protein necessary for cell proliferation
[10]. There was no significant difference in the percentage of
Ki67+ cells over the total number of cells (DAPI+) between
the different treatment groups (Fig. 1c, d). Western blot did
not detect the cleaved form of Caspase-3 (Fig. 1e) in any ofthe experimental groups. No apoptotic cells were detected in
the treatment groups by TUNEL staining (Fig. 1f). Our re-
sults suggest that long-term HighGlu treatment did not
affect macrophage differentiation from bone marrow cells
and did not induce macrophage apoptosis.
Short-term and long-term high glucose treatment on
BMDM immune gene expression
Next, we investigated the impact of HighGlu on macro-
phage gene expression. The exposure of naïve BMDMs
generated under NormGlu to HighGlu for 24 h (short-term
HighGlu) increased IL-1β expression but did not
affect the expression of inducible nitric oxide synthase
2 (iNOS), tumour necrosis factor-α (TNFα), interleu-
kin 6 (IL-6), interleukin 12p40 (IL-12p40), arginase-1
(Arg-1), and interleukin 10 (IL-10) (Fig. 2a). When
M1 macrophages were exposed to HighGlu for 24 h,
the expression of IL-1β was significantly increased
(Fig. 2b). Short-term HighGlu treatment did not affect
other genes expression in both M1 (Fig. 2b) and M2 mac-
rophages (Fig. 2c). NO production was also not affected
(Fig. 2d). The results suggest that short-term HighGlu en-
hances macrophage pro-inflammatory response.
BMDMs generated under long-term HighGlu condi-
tion had significantly higher levels of IL-1β expression,
but the expression of other immune genes such as iNOS,
TNFα, IL-6, IL-12p40, Arg-1 and IL-10 was not affected
compared with BMDMs generated under NormGlu condi-
tions (Fig. 2e). Following M1 polarization, BMDMs gener-
ated under long-term HighGlu conditions expressed lower
levels of IL-12p40, but higher levels of TNFα and IL-1β com-
pared to M1 BMDMs under NormGlu conditions (Fig. 2f).
Long-term HighGlu treatment also reduced the expression
of iNOS, although not significantly (Fig. 2f). In contrast with
the iNOS expression, NO production was significantly lower
in long-term HighGlu treated M1 macrophages (Fig. 2h).
Interestingly, IL4-induced upregulation of Arg-1 and IL-10
was significantly enhanced in long-term HighGlu treated
BMDMs (Fig. 2g). Mannitol did not affect the expression
levels of the aforementioned cytokines in BMDMs (data not
shown). The results suggest that long-term HighGlu may
alter macrophage response to cytokine stimulations. In re-
sponse to LPS + IFNγ stimulation, they have reduced ability
to generate NO, but have increased TNFα and IL-1β expres-
sion. They also appear to be more sensitive to Th2-type cyto-
kine (e.g., IL-4) stimulation.
To investigate if the increased IL-1β mRNA expression
in HighGlu-treated macrophages resulted in higher
levels of protein secretion, IL-1β levels in culture super-
natants were measured using ELISA. The results show
that the levels of IL-1β are undetectable in naïve
BMDMs (data not shown). LPS + IFNγ stimulation and
high glucose significantly increased IL-1β production
(Fig. 3a-b).
Fig. 1 Long-term HighGlu does not affect differentiation, viability or proliferation of BMDMs. Bone marrow cells were cultured for 7 days under
NormGlu, HighGlu or Mannitol (osmolarity control) conditions. a Flow cytometric analysis showing the percentage of F4/80+ cells differentiated
under the three culture conditions. b MTT assay demonstrating the cell viability of BMDMs. c Graph showing the percentage of Ki67+ cells. d
Representative images of Ki67+ cells (red), counterstained with DAPI (blue). e Western blot for Casp3 using protein extracts from the three culture
conditions. BMDMs treated with TNFα were used as a positive control. f Representative images of TUNEL assay (red). DNase-treated BMDMs were
used as a positive control. Scale bars = 25 μm. Data are represented as mean ± SEM. One-way ANOVA followed by Tukey’s multiple comparison
post hoc test was performed
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Glu conditions responded differently to LPS + IFNγ and
IL-4 stimulations, we investigated whether they expressed
different levels of relevant receptors. Short-term HighGlu
only increased Toll-like receptor 4 (TLR-4) expression in
BMDMs (Fig. 3c), whereas long-term HighGlu significantly
increased the expression of TLR-4, interferon gamma re-
ceptor 1 (IFNγR1) and interferon gamma receptor 2
(IFNγR2) (Fig. 3d). Interestingly, the expression levels of
interleukin 4 receptor, alpha (IL4ra) remained unchanged
in both short-term and long-term HighGlu treated macro-
phages (Fig. 3c-d).
The effect of long-term high glucose on BMDM
phagocytosis and bactericidal function
The evident difference between short-term and long-
term HighGlu on macrophage response to cytokinestimulation prompted us to further investigate other
macrophage functions such as phagocytosis. Using the
pHrodo S. aureus bioparticles phagocytosis assay, we did
not observe any difference between macrophages treated
with or without short-term HighGlu (Additional file 1:
Figure S1). However, in macrophages generated under
HighGlu significantly reduced phagocytosis was observed
after 1.5 h and 2 h of bioparticle incubation compared
with BMDMs in NormGlu and Mannitol conditions
(Fig. 4a). Long-term Mannitol treatment did not affect
macrophage phagocytosis (Fig. 4a).
To further confirm the effect of long-term HighGlu on
macrophage phagocytic function, we harvested elicited
peritoneal macrophages from STZ-induced diabetic
mice, ex-diabetic mice and healthy controls and per-
formed the same phagocytosis assay. Peritoneal macro-
phages from diabetic mice showed significantly reduced
Fig. 2 (See legend on next page.)
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Fig. 2 The effects of short and long-term HighGlu on BMDM gene expression and NO production. Bone marrow cells were cultured for
7 days under NormGlu (white bars) or HighGlu (black bars) conditions. They were then plated and stimulated with LPS + IFNγ (M1) or IL-4
(M2) for 24 h. For short-term HighGlu, cells differentiated under NormGlu, were exposed to HighGlu for 24 h along with M1 or M2
stimulation. a-c qRT-PCR showing the expression of immune-related genes in naïve (a), LPS + IFNγ (b) or IL-4 (c) treated BMDMs after
short-term exposure to HighGlu treatment. d Graph showing the concentration of NO in supernatants of naïve and LPS + IFNγ-treated
BMDMs under NormGlu or short-term HighGlu conditions. e-g qRT-PCR showing the expression of immune-related genes in naïve (e),
LPS + IFNγ (f) or IL-4 (g) treated BMDMs after long-term exposure to HighGlu treatment. h NO concentration in the supernatants of naïve
and LPS + IFNγ stimulated BMDMs after long-term HighGlu. Data are represented as mean ± SEM. Unpaired, two-tailed Student’s t test was
performed. * p < 0.05, ** p < 0.01, *** p < 0.001
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healthy control mice (Fig. 4b). Interestingly, peritoneal
macrophages from ex-diabetic mice had normal levels of
phagocytosis, suggesting that hyperglycaemia-induced
phagocytosis impairment is reversible.
The pHrodo S. aureus bioparticles assay not only detects
the uptake of bacterial particles, but also measures the for-
mation of phagolysosomes, a pivotal action by macrophage
to kill bacteria. The bactericidal function of macrophages
was further assessed by challenging macrophages with live
pathogenic bacteria. After 1 h incubation of P. aeruginosa
PAO1 with BMDMs, extracellular as well as intracellular
bacteria were quantified. Extracellular bacterial colonies
were comparable between the different groups (Fig. 4c),Fig. 3 The effects of short- and long-term HighGlu on IL-1β secretion and
7 days under NormGlu (white bars) or HighGlu (black bars) conditions. The
short-term HighGlu, cells differentiated under NormGlu, were exposed to H
levels of IL-1β in the supernatants of M1 BMDMs exposed to short-term (a)
and cytokine receptors in naïve BMDMs exposed to short-term (c) or long-
tailed Student’s t test was performed. * p < 0.05, ** p < 0.01suggesting that the same number of bacteria were taken up
by the different macrophages. Interestingly, the colonies of
intracellular surviving bacteria in macrophages gener-
ated under long-term HighGlu conditions were sig-
nificantly higher than those in macrophages generated
under NormGlu and Mannitol conditions (Fig. 4c). The
results suggest that long-term HighGlu impairs bacteri-
cidal ability of macrophages.
To understand if the reduced phagocytosis in BMDMs
generated under HighGlu conditions seen at 1.5 h and 2 h
(Fig. 4a) is related to altered scavenger receptor expression,
the expression of cell surface receptors CD16/32, CD36
and CD206 in different types of BMDMs was examined by
flow cytometry. Our results show that the expression levelsLPS/cytokine receptor expression. Bone marrow cells were cultured for
y were then plated and stimulated with LPS + IFNγ (M1) for 24 h. For
ighGlu for 24 h along with M1 stimulation. a-b ELISA showing the
or long-term (b) HighGlu. c-d qRT-PCR showing the expression of LPS
term (d) HighGlu. Data are represented as mean ± SEM. Unpaired, two-
Fig. 4 Long-term HighGlu and diabetes mellitus affect the phagocytic and bactericidal functions of macrophages. Bone marrow cells were
cultured for 7 days under NormGlu, HighGlu or Mannitol conditions. Peritoneal macrophages were isolated from control, diabetic (DM) or
ex-diabetic (ex-DM) mice. Phagocytosis was assessed using pHrodo S. aureus bioparticles and bactericidal function using P. aeruginosa PAO1
cultures. The expression of CD16/32, CD36 and CD206 was measured by flow cytometry. a Phagocytic activity of BMDMs cultured under NormGlu
(red), HighGlu (green) or Mannitol (blue) conditions. b Phagocytic activity of peritoneal macrophages. c Bactericidal function of BMDMs. d Mean
fluorescence intensity of CD16/32, CD36 and CD206 in BMDMs. White bars: NormGlu, black bars: HighGlu, grey bars: Mannitol. Data are
represented as mean ± SEM. Two-way ANOVA with bonferroni correction was performed in (a); * p < 0.05, *** p < 0.001 relative to
NormGlu, ♯♯♯ p < 0.001 relative to Mannitol. One-way ANOVA followed by Tukey’s multiple comparison post hoc test was performed in
(b-d); * p < 0.05, ** p < 0.01, *** p < 0.001
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pression of CD36 and CD206 was significantly lower in
BMDMs cultured under HighGlu conditions compared to
those cultured under NormGlu or Mannitol conditions
(Fig. 4d).The effect of long-term high glucose on macrophage
glucose metabolism and mitochondrial oxygen
consumption
Immune cells’ function is governed by their metabolisms
[11]. We hypothesize that long-term HighGlu treatment may
affect macrophage function through regulating their meta-
bolic pathways. In the Glycolysis Stress assay, BMDMs were
incubated in basal medium (medium without added glucose,
supplemented with glutamine) for 1 h followed by the vari-
ous stimulations depicted in Fig. 5a. The non-glycolytic
(baseline) extracellular acidification rate (ECAR) of naïve
BMDMs in all culture conditions was similar (Fig. 5a). The
addition of glucose and subsequently oligomycin resulted in
a rapid increase in ECAR (Fig. 5a). Both short-term (24 h,
Fig. 5a, b) and long-term (7 days, Fig. 5c, d) HighGlu treat-
ment significantly reduced BMDM response to glucose andoligomycin stimulations. Specifically, the short-term High-
Glu treatment reduced glycolysis and glycolytic capacity
(Fig. 5b); whereas long-term HighGlu reduced glycolytic
capacity and glycolytic reserve (Fig. 5d).
The Cell Mito Stress assay showed that the basal respir-
ation rates were at similar levels in macrophages gener-
ated under the different conditions (Fig. 6a, c). Blocking
ATP synthase using oligomycin allows the measurement
of ATP production by mitochondria. Macrophages gener-
ated under different conditions had the same levels of
mitochondrial ATP production (Fig. 6). In addition, the
proton leakage, maximal respiration, spare capacity,
non-mitochondrial respiration (Fig. 6b, d) were compar-
able in different macrophages.
Our results suggest that mitochondrial oxygen consump-
tion was not affected by short-term or long-term high glu-
cose treatment. The reduced glycolysis might contribute to
high glucose-mediated altered macrophage functions.Discussion
In this study, we show that BMDMs generated under
long-term high glucose conditions pose a number of
Fig. 5 HighGlu treatments affect the glycolytic pathway of BMDMs. Bone marrow cells were cultured for 7 days under NormGlu, HighGlu or
Mannitol conditions (long-term treatments). For short-term HighGlu and Mannitol, cells differentiated under NormGlu, were exposed to HighGlu
or Mannitol for 24 h, respectively. The glycolysis stress assay was performed using the Seahorse XFe96 analyzer. a Representative profile after
glycolysis stress assay showing the ECAR of BMDMs exposed to short-term NormGlu (red), HighGlu (green) or Mannitol (blue). b Graph showing
non-glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve of BMDMs after short-term NormGlu (white bars), HighGlu (black
bars) and Mannitol (grey bars) treatments. c Representative profile after glycolysis stress assay showing the ECAR of long-term treated BMDMs. d
Graph showing non-glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve of BMDMs after long-term exposure to the
different conditions. Data are represented as mean ± SEM. One-way ANOVA followed by Tukey’s multiple comparison post hoc test was
performed; * p < 0.05, ** p < 0.01, *** p < 0.001
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glucose conditions. Under naïve conditions BMDMs ex-
press higher levels of IL-1β and upon LPS + IFNγ stimula-
tion they produce higher levels of TNFα but lower levels of
nitric oxide. They also express higher levels of Arg-1 and
IL-10 upon IL-4 stimulation compared with BMDMs gen-
erated under normal glucose conditions. The phagocytosis
and bactericidal activity of these cells appear to be im-
paired. The phenotype and function of these long-term
high glucose treated cells mirror the monocyte/macrophage
functions observed in diabetic animals and patients, i.e.
they are pro-inflammatory and contribute to the develop-
ment of diabetic complications, but have reduced defence
and tissue repair capacities. This in vitro system is there-
fore, a good model to study diabetes-mediated immune
dysfunction.
Dysregulated innate immune activation is known to con-
tribute to diabetic complications [1, 5, 6, 12]; whether this
is due to the intrinsic change of innate immune cells or thenoxious tissue microenvironment remains elusive. Results
from diabetic animals and patients are controversial. The
volume of bone marrow and the hematopoietic fraction
were reduced in STZ-induced diabetic mice [13]. The pop-
ulations of circulating F4/80+, CD11b+, CCR2+ or Ly6G+
cells in diabetic mice were reported to be reduced in some
studies [14], but increased in others [6]. Mononuclear cells
from diabetic patients secrete less IL-1 and IL-6 after LPS
stimulation [15, 16]. Increased glycation is known to inhibit
IL-10 and TNFα production by immune cells [17], which
suggests that the lower cytokine production may be a con-
sequence of diabetes-mediated intrinsic defect in these
cells. In our study, long-term HighGlu did not affect the
differentiation of bone marrow cells into F4/80+ macro-
phages, but the function of these cells appears to be altered
(see below).
Nitric oxide (NO) is a signalling molecule critically
involved in inflammation [18, 19]. Sustained production
of NO endows macrophages with cytostatic or cytotoxic
Fig. 6 HighGlu treatments has no effect on the mitochondrial oxidative phosphorylation of BMDMs. Bone marrow cells were cultured for 7 days
under NormGlu, HighGlu or Mannitol conditions (long-term treatments). For short-term HighGlu and Mannitol, cells differentiated under NormGlu,
were exposed to HighGlu or Mannitol for 24 h, respectively. The Mito stress assay was performed using the seahorse XFe96 Analyzer. a
Representative profile after Mito stress assay showing the OCR of BMDMs exposed to short-term NormGlu (red), HighGlu (green) or Mannitol
(blue). b Graph showing basal OCR, proton leakage, maximal respiration, spare capacity, non-mitochondrial respiration and ATP production of
BMDMs after acute NormGlu (white bars), HighGlu (black bars) and Mannitol (grey bars) treatments. c Representative profile after Mito stress assay
showing the OCR of long-term treated BMDMs. d Graph showing the different aspects of mitochondrial oxidative phosphorylation pathway of
BMDMs after long-term exposure to the different conditions. Data are represented as mean ± SEM. One-way ANOVA followed by Tukey’s multiple
comparison post hoc test was performed
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pathogens [20]. BMDMs cultured under long-term high
glucose conditions produced less NO upon LPS + IFNγ
stimulation, although the mRNA expression levels of iNOS
did not show any significant reduction. It is possible that
other isoforms of NOS (e.g., eNOS) or the availability of ar-
ginine in long-term high glucose treated macrophages may
be affected. Additionally, the long-term high glucose may
also affect the NO production at posttranscriptional, transla-
tional and posttranslational levels [21] . They also express
lower levels of IL-6 and IL-12p40 and have impaired phago-
cytic and bactericidal functions. Reduced NO production has
been reported in high glucose treated human macrophage
J774 cells [22]. Increased NO production [23] and lower
ROS production [24] has been observed in peritoneal macro-
phages from diabetic rats. BMDMs and peritoneal macro-
phages from the NOD mice had reduced ability to
phagocytise apoptotic cells [25–27]. Reddy and colleagues
[28] reported reduced expression of iNOS, IL-10 and Arg-1in BMDM from db/db mice. All these results suggest that
diabetes or long-term high glucose down-regulates iNOS ex-
pression and reduces NO production. The molecular mech-
anism underlying the differential responses to cytokine
stimulations between short-term and long-term HighGlu
treated macrophages remains elusive. We believe that the
long-term HighGlu treated macrophages resemble their
in vivo counterparts in diabetic conditions.
Despite reduced NO production following long-term
HighGlu treatment, these cells express higher levels of TNFα
and IL-1β, suggesting a pro-inflammatory phenotype. This
agrees with a previous study, which showed that the myeloid
cells recruited to wounds of diabetic mice are intrinsically
primed to be more pro-inflammatory than those of
non-diabetic mice [29]. TNFα and IL-1β were also higher in
cultures of peritoneal macrophages in STZ-induced diabetic
rats comparing to control rats [23]. High glucose leads to
increased production of IL-1β and TNFα via the NF-κB
pathway [30, 31]. Interestingly, the long-term HighGlu
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IL-10 following IL-4 stimulation, suggesting an enhanced
M2 phenotype. A previous study by Cucak and colleagues
[32] reported an M2-type phenotype in macrophages from
28-week db/db mice. Our data suggest that long-term high
glucose sensitizes macrophages to cytokine stimulations i.e.,
they present exaggerated responses to both Th1- and
Th2-type cytokine stimulation, which may contribute to the
dysregulated immune response observed in diabetic patients.
The molecular mechanism underlying long-term High
Glu-mediated alteration of macrophage function remains
unknown. Glucose uptake in macrophages is mediated
predominately by glucose transporter 1 [33], which does
not rely on insulin signalling. We have found that the
HighGlu treatment impairs macrophage glycolytic
capacity and glycolytic reserve without affecting mito-
chondrial ATP production and oxidative respiration.
Glycolytic capacity is a measure of the maximum rate of
conversion of glucose to pyruvate or lactate by a cell,
and the difference between basal glycolysis and glycolytic
capacity is known as glycolytic reserve. The basal glycolysis
did not differ between BMDMs under NormGlu and
HighGlu. Therefore, the reduction in glycolytic reserve may
contribute predominately to impaired glycolytic capacity.
Glycolytic reserve is an important bioenergy source in re-
sponse to increases in ATP demand. Our results suggest that
long-term HighGlu treatment may limit macrophage energy
supply when additional ATP is needed. The LPS-induced
proinflammatory macrophages are known to be fuelled by
glycolysis [34]. High levels of glycolysis generate NADPH to
support NO and ROS production. The reduced glycolytic
capacity may explain the lower levels of NO production and
impaired bactericidal activity in long-term HighGlu treated
macrophages. It may also be related to the reduced phago-
cytosis of these cells, as we have recently shown that macro-
phage phagocytic function is directly associated with
glycolytic function [35].
Conclusions
Our study shows that long-term HighGlu sensitizes macro-
phages to cytokine stimulations, but reduces phagocytosis
and bactericidal function of macrophages. The latter may
be related to the reduced glycolytic capacity and glycolytic
reserve of these cells. Further understanding of the link be-
tween altered glucose metabolism and dysregulated macro-
phage function in diabetes will be important to uncover the
immunopathogenesis of diabetic complications.
Methods
Animals
C57BL/6 J mice were purchased from Harlan and housed
under specific pathogen-free conditions with free access
to normal chow and water. Diabetes was induced in
12-week male C57BL/6 J mice by intraperitoneal injectionof streptozotocin (STZ) at 50 mg/kg for 5 consecutive
days [36]. Non-fasting glucose level was measured 1 week
after the last injection; mice with glucose level over
13 mmol/l were considered diabetic. If the glucose
level was reversed back to normal within 2 months
after STZ injection, the mice were considered as
ex-diabetic. Body weight was monitored monthly
(Additional file 2: Figure S2). Mice were sacrificed
3 months after STZ injection and peritoneal macro-
phages were harvested from diabetic mice (n = 3),
age-matched controls (n = 3) and ex-diabetic mice (n
= 3). Mice were euthanized by exposure to CO2. All
animal procedures were approved by the UK Home
Office under the Home Office Animal Act (1986)
(PPL 2773).
Bone marrow-derived macrophage culture
Bone marrow derived macrophages (BMDMs) were cul-
tured from 8 to 12-week-old C57BL/6 J mice using a
protocol described previously [37]. Briefly, bone marrow
cells were cultured in complete DMEM (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) supplemented
with 10% heat-inactivated foetal bovine serum (FBS) and
20% L929-conditioned media as a source of macrophage
colony-stimulating factor (M-CSF) [37]. The phenotype
of BMDMs was confirmed by flow cytometry as being
F4/80+ and CD11b+ (data not shown).
High glucose treatment of BMDMs
Three types of culture media were used in the in vitro
studies: normal glucose DMEM (NormGlu), high glu-
cose DMEM (HighGlu), osmolarity control (Mannitol)
medium. NormGlu is the standard DMEM (5.5 mM glu-
cose, Thermo Fisher Scientific). HighGlu is the standard
DMEM supplemented with additional 25 mM glucose.
Previous studies have used glucose concentration
ranging from 25 to 40 mM to mimic diabetic condition
in cell cultures [38, 39]. Osmolarity control medium
(Mannitol) is the standard DMEM supplemented with
25 mM Mannitol [40]. BMDMs were treated for
short-term (24 h) or long-term (7 days). Figure 7 shows
the experimental design and work flow.
Short-term treatment
BMDMs were generated from bone marrow cells under
NormGlu condition. The cells were collected on day 7
and plated in 12- or 96-well plates with NormGlu, High-
Glu or Mannitol for further investigations.
Long-term treatment
BMDMs were generated under NormGlu, HighGlu or
Mannitol conditions. On day 7, cells were harvested and
plated in 12- or 96-well plates for further investigations.
Fig. 7 Schematic illustration showing the experimental setup. BM was collected and cultured under NormGlu, HighGlu or Mannitol conditions for
7 days (long-term treatments). BMDMs were then counted and stimulated with LPS + IFNγ (M1) or IL-4 (M2) for 24 h. BMDMs differentiated under
NormGlu were exposed to short-term HighGlu or Mannitol, along with M1 or M2 stimulations for 24 h
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BMDMs were seeded in 12-well plates at a density of
5 × 105 cells per well. The cells were polarized into M1
with 50 ng/ml LPS (Sigma-Aldrich, St. Louise, Missouri,
USA) + 100 ng/ml IFNγ (Bio-Techne, Minneapolis, Minne-
sota, USA) or M2 with 20 ng/ml IL-4. (Bio-Techne, Minne-
apolis, Minnesota, USA) The supernatants were collected
24 h after cytokine stimulation and nitric oxide (NO)
was measured using the Griess Reagent System (Pro-
mega, Madison, Wisconsin, USA), according to manufac-
turer’s instructions. IL-1β in BMDM supernatants was
measured using the mouse IL-1 beta/IL-1F2 DuoSet ELISA
kit (DY401, Bio-Techne, Minneapolis, Minnesota, USA) ac-
cording to manufacturer’s instructions. Cells were collected
for flow cytometry, protein or RNA extraction.
Assessment of BMDMs cell death and proliferation
Cell death of BMDMs cultured under different glucose
conditions (NormGlu, HighGlu or Mannitol control)
were measured using Thiazolyl Blue Tetrazolium Blue
(MTT, Sigma-Aldrich, St. Louise, Missouri, USA) [41]
and TUNEL assay (In Situ Cell Death Detection Kit,
TMR red, Roche, Basel, Switzerland), according to man-
ufacturer’s instructions. Cell proliferation was assessed
by Ki67 (1:100, clone: SolA15, Thermo Fisher Scientific)
immunofluorescence, using a standard protocol [42]. For
these assays, cells were counted on the day of bone
marrow extraction and 1 × 104 cells were plated in a
96-well plate. After 7 days of differentiation the assays
were performed.
For MTT assay, cells were incubated in 0.5 mg/ml
MTT for 4 h at 37 °C. The MTT solution was then re-
placed by 200 μl DMSO per well and cells were incu-
bated for 30 min at 37 °C until the purple formazancrystals were dissolved. Absorbance was measured at
562 nm using the Fluostar Omega plate reader (BMG
Labtech, Ortenberg, Germany). For the TUNEL assay,
cells were fixed in 2% PFA for 15 min at room
temperature. After several washes with PBS, cells were
incubated with the TUNEL-mix for 1 h at 37 °C. After
washes with PBS, cells were imaged using an IX51
inverted fluorescent microscope (Olympus, Southend,
UK). Cells were treated with DNase (Thermo Fisher
Scientific) for 10 min at room temperature, before the
addition of the TUNEL-mix, as a positive control.
Western blot
Total protein was extracted in RIPA buffer supplemented
with 10% proteinase inhibitor cocktail (Sigma-Aldrich) and
quantified using the BCA assay (Thermo Fisher Scientific).
The same amount of denatured proteins from each treat-
ment group was separated on a 12% SDS-PAGE gel and
transferred onto polyvinylidene fluoride (PVDF) mem-
branes. Membranes were incubated with antibody against
mouse Caspase-3 (1:100, Millipore, Darmstadt, Germany)
at 4 °C overnight, followed by anti-rabbit-HRP (1:5000,
Agilent Technologies, Santa Clara, California, USA) for 1 h
at room temperature. Protein from BMDMs stimulated
with 20 ng/ml TNFα for 3 h at 37 °C was used as a positive
control for the cleaved Caspase-3. Membranes were devel-
oped using enhanced chemiluminescence (Clarity™ Western
ECL Blotting Substrates, BioRad, Hercules, California, USA)
and corresponding bands were detected using Syngene
G-Box imaging system (Syngene, Cambridge, UK).
Quantitative real time RT-PCR
Total RNA was extracted using the RNeasy mini kit
(Qiagen, Hilden, Germany) and cDNA was synthesised
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Fisher Scientific) with random primers (Thermo Fisher
Scientific) following the manufacturer’s instructions.
QRT-PCR was performed using the LightCycler 480
SYBR Green Master Mix (Roche). The primer sequences
used in the study are shown in Table 1. Relative gene ex-
pression was normalised to 18S ribosomal RNA (Rn18s)
using the 2-ΔΔCT method.
Flow cytometric analysis
Single-cell suspensions were stained for cell surface markers
using specific antibodies following protocols published
previously [43]. All samples were analysed using a FACS
Canto II (BD biosciences, UK) and data were processed
using FlowJo Software (version 7 for Windows, Tree Star,
Ashland, OR, USA). The following antibodies were used:
F4/80 (clone: BM8, Thermo Fisher Scientific), CD16/32
(clone: 2.4G2, Thermo Fisher Scientific); CD36 (clone:
HM36, Biolegend, San Diego, California, USA), CD206
(clone: C068C2, Biolegend).
Macrophage phagocytosis
Phagocytosis was conducted using the pHrodo S. aureus
bioparticles conjugated phagocytosis kit (Thermo Fisher
Scientific) following the manufacturer’s instructions [35].
Briefly, BMDMs or peritoneal macrophages were seeded
onto 96-well black-walled plates at a density of 5 × 104
per well for 24 h before adding the bioparticles. CultureTable 1 Primers used for RT-PCR
Name Forward Reverse
Arg-1 TTATCGGAGCGCCTTTCTCAA TGGTCTCTCACGTCATA
CTCTGT
IFNγR1 GGTTGCTCCTCTTACCGTCT GTGCGGTGTGACAAGT
GAAT
IFNγR2 TGCTTCACCCTGTTCCTCAA CTGGTTCACGGTGTTTG
GAG
IL-10 TGCAGGACTTTAAGGGTTA
CTTGG
GGCCTTGTAGACACCTT
GGTC
IL-12p40 GACATCATCAAACCAGACC
CGCC
GCCTTTGCATTGGACTT
CGGT
IL-1β TCCTTGTGCAAGTGTCTGA
AGC
ATGAGTGATACTGCCT
GCCTGA
IL4ra TGGCTGCTGACCTGGAA
TAA
TCAGCCTGGGTTCCTT
GTAG
IL-6 TCTGCAAGAGACTTCCAT
CCAGT
TCTGCAAGTGCATCATCGTTGT
iNOS GGCAAACCCAAGGTCTA
CGTT
TCGCTCAAGTTCAGCTTGGT
Rn18s AGGGGAGAGCGGGTAA
GAGA
GGACAGGACTAGGCGGAACA
TLR-4 TCCTGGCTAGGACTCTG
ATCAT
TCCAGCCACTGAAGTTCTGA
TNFα GCCTCTTCTCATTCCTGCTT CTCCTCCACTTGGTGGTTTGmedium with bioparticles only was served as a negative
control. Fluorescence intensity was measured 1 h, 1.5 h
and 2 h after the addition of bioparticles using the
Fluostar Omega plate reader (BMG Labtech). The net
fluorescence intensity was the difference between the
fluorescence intensity from the experimental wells and
that from the negative control wells [35].
Bacterial killing assays
A colony of Pseudomonas aeruginosa PAO1 was selected
from a cetrimide agar plate and inoculated into 10 mL of
LB broth (Sigma-Aldrich). This was grown overnight at
37 °C in an orbital shaker at 160 rpm. The cells were har-
vested by centrifugation in an Eppendorf centrifuge 5810R
at 4000 rpm for 10 mins and resuspended in 40 ml of fresh
LB broth. They were grown to log phase for 4–6 h at 37 °C
on a rotary shaker at 160 rpm. The optical density of the
bacterial culture was measured at 600 nm (WPA biowave).
To assess their bactericidal activity, 1 × 106 BMDMs were
plated in 12-well plates. P. aeruginosa was added to the
wells at multiplicity of infection (MOI) 1:10 (1 × 107 CFU/
ml). The BMDM/P. aeruginosa co-culture was incubated
for 1 h at 37 °C. The coculture was then centrifuged at
1500 rpm for 5 min and the supernatant removed. The
supernatant was serial diluted in PBS at 10− 4, 10− 5, 10− 6
and 10− 7 and plated onto cetrimide agar (Sigma-Aldrich).
Saponin (Sigma-Aldrich) at 1:1000 dilution in PBS was
added to all pellets and incubated for 5 min. The digested
pellets were serial diluted in PBS at 10− 4, 10− 5, 10− 6 and
10− 7 and plated onto cetrimide agar. All cetrimide plates
were incubated for 18 h and CFU/mL were then calculated.
Bioenergetic profile of BMDMs
BMDMs metabolic profiles were assessed using Seahorse
XF Glycolysis Stress Test kit and Cell Mito Stress Test
kit with a Seahorse XFe96 Analyzer (Agilent Technologies)
following manufacturer’s instructions. Glycolytic activ-
ities were assessed by measuring the Extracellular
Acidification Rates (ECAR) and mitochondrial activities
were assessed by measuring the Oxygen Consumption
Rates (OCR). Data were normalised with the total cell
number and expressed as mpH/min/104 cells for ECAR or
pmol/min/104 cell for OCR.
Statistical analysis
Data were presented as mean ± standard error (SEM).
Unpaired, two-tailed Student’s t test was used for
two-group comparisons. One-way ANOVA was used
to compare the means of multiple groups; Tukey’s
multiple comparisons were used for post hoc test
when samples had equal variances. Student t test with
Welch’s correction was employed when the equal
variance assumption was not met. P < 0.05 was con-
sidered statistically significant.
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Additional file 1: Figure S1. Phagocytosis of BMDMs exposed to
short-term HighGlu. Bone marrow cells were differentiated under
NormGlu and then exposed to HighGlu for 24 h. Phagocytosis was
assessed using pHrodo S. aureus bioparticles. Data are represented as
mean ± SEM. Two-way ANOVA with bonferroni correction was performed.
(TIF 257 kb)
Additional file 2: Figure S2. Body weights of control and diabetic (DM)
mice, before and after STZ injections. Mice were weighted (time point 0)
and STZ (50 mg/kg) was injected for 5 consecutive days. One week after
the last STZ injection (time point 1), mice had elevated blood glucose
levels (diabetic-DM). Weights were monitored every 4 weeks until the
end of the experiment. Data are represented as mean ± SEM. Two-way
ANOVA with bonferroni correction was performed; *** p < 0.001.
(TIF 256 kb)
Abbreviations
ATP: Adenosine triphosphate; BMDMs: Bone marrow derived macrophages;
ECAR: Extracellular acidification rate; HighGlu: High glucose (30.5 mM);
NormGlu: Normal glucose (5.5 mM); OCR: Oxygen consumption rate;
ROS: Reactive oxygen species; STZ: Streptozotocin
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